Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CHAMP App Cardiac Study and Repository (CHAMP)

13. november 2026 oppdatert av: Lori Erickson

CHAMP App Cardiac Study: Evaluering av programvarefunksjoner for asynkron overvåking av barn med kompleks medfødt hjertesykdom i hjemmemiljøet og datalageret

This is a multi-site research study with an optional research repository that will consist of clinically derived data and photographic or video images of patients in the home setting with complex health conditions to evaluate the safety and efficacy of the CHAMP® software platform, with data and photographic or video images input and/or uploaded by the parent or other legally authorized representative (LAR) of patients with complex congenital heart disease as a target population.

Studieoversikt

Status

Påmelding etter invitasjon

Intervensjon / Behandling

Detaljert beskrivelse

Study objectives

  1. To evaluate whether data collection and transmission through the CHAMP software platform improves communication between health care providers and parents/LAR that positively affects the care of children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated
  2. To determine the accuracy of data obtained regarding observation by parent or caregiver of the condition of children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated.
  3. To evaluate the use of the CHAMP App for clinical purposes, including user satisfaction with the data entry, parental self-management, and transmission capabilities.
  4. To evaluate the real-world performance analytics (RWPA) of the CHAMP software platform for transfer of parent-entered data for children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated.

Endpoints

  1. To demonstrate that parents and caregivers for children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated can accurately identify and transmit to healthcare providers specific health-related data including intake of food, fluids and mediations; output, including urination, defecation, and vomiting; weight; vital signs including oxygen saturation as measured by pulse oximetry; heart rate as measured either by a heart rate monitor or manually by the parent or caregiver; and temperature, measured by a reliable thermometer; and the value and reliability of videos provided by parents and caregivers regarding behavior of pediatric study participants for use in evaluating participant's health status.
  2. To demonstrate that data obtained through the use of devices such as pulse oximeters, as entered into the app by parents and caregivers, provide valuable information regarding the health status of children with Complex Diagnoses in a home setting.
  3. To demonstrate characteristics of CHAMP through real world health analytics (RWHA), user experience analytics (UX), and product performance analytics (PPA).

The study duration is open-ended for safety, effectiveness, and performance of the CHAMP app. Unless consent is withdrawn, data will be kept and used for data analysis and, if consented to the research repository for multi-site research purposes indefinitely. At age 18, previously pediatric patients may be approached for reconsent.

Studietype

Observasjonsmessig

Registrering (Antatt)

1000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Children's National Hospital
    • Florida
      • Miami, Florida, Forente stater, 33155
        • Nicklaus Variety Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70118
        • Children's Hospital New Orleans
    • Missouri
      • Kansas City, Missouri, Forente stater, 64108
        • Children's Mercy Hospital
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • Cincinnati Children's Hospital Medical Center
      • Columbus, Ohio, Forente stater, 43205
        • Nationwide Children's Hospital
    • Texas
      • Forth Worth, Texas, Forente stater, 76104
        • Cook's Children's
      • Houston, Texas, Forente stater, 77030
        • Children's Memorial Hermann Hospital
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • Primary Children's Hospital/University of Utah

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 18 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Pediatric patients with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated in the home setting through a multi-regional approach.

Parents who utilize their CHAMP App and the healthcare team that log-in are also part of the CHAMP App study.

Beskrivelse

Inclusion Criteria:

  • Age 0-17 years with a parent/Legally authorized representative
  • Diagnosed with a complex health condition in which asynchronous monitoring in the home setting is appropriate.
  • Pediatric patient's cardiac care team has decided that the patient's treatment plan may benefit from remote home monitoring.
  • Institution that the subject is followed through clinically has been an approved as site for the CHAMP app study with Children's Mercy Kansas City.

Adult participants

  • Parents/Legally authorized representatives of pediatric subject.
  • Healthcare team users at an institution that is an approved site for the CHAMP app Study with Children's Mercy Kansas City.

Exclusion Criteria:

  • Inability to be discharged to care in the home setting.
  • Those not meeting the above inclusion criteria.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: OTHER

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Human factors/usability engineering: Login failures
Tidsramme: Over a 3 month period

Rate of attempts of log-in failures

Over a 3 month period
Human factors/usability engineering: Imprecision
Tidsramme: Over a 3 month period

Rate of data values reported with imprecision

Over a 3 month period
Clinical Safety: Anticipated adverse events
Tidsramme: Over a 3 month period

Anticipated Adverse event rates

Over a 3 month period
Clinical Safety: Event resolution- anticipated
Tidsramme: Time in days, reported over the last 3 months

Time to resolve anticipated adverse events

Time in days, reported over the last 3 months
Clinical Safety: Unanticipated Adverse events
Tidsramme: Time in days, reported over the last 3 months

Unanticipated adverse event rates

Time in days, reported over the last 3 months
Clinical Safety: Event resolution- unanticipated
Tidsramme: Time in days, reported over the last 3 months

Time to resolve unanticipated adverse events

Time in days, reported over the last 3 months
Health Benefits: Adherence
Tidsramme: Measurement of adherence to daily data entry per each patient/parent over 3 month period on non-hospitalized days, during the study period

Rate of adherence to daily data entry

Measurement of adherence to daily data entry per each patient/parent over 3 month period on non-hospitalized days, during the study period
User Satisfaction: Complaints
Tidsramme: Over a 3 month period

Complaint rates via the healthcare team web portal

Over a 3 month period
User Satisfaction CHAMP Video
Tidsramme: through study completion, an average of 9 months

Feedback from healthcare team will be received via treatment endpoint survey questions. Likert scale questions 1-strongly disagree to 5 strongly agree (Using CHAMP videos for the interstage monitoring of this patient improved clinical decisions for the home monitoring team). Available to put in comments.

through study completion, an average of 9 months
User Satisfaction: Communication
Tidsramme: through study completion, an average of 9 months

Feedback from healthcare team will be received via treatment endpoint survey questions Likert scale questions 1-strongly disagree to 5 strongly agree ( Using CHAMP for the interstage monitoring of this patient improved communication with the parents at home.) Available to put in comments.

through study completion, an average of 9 months
User Engagement
Tidsramme: Over a 3 month perriod

Total number of registered users (Active, treatment endpoint reached) and data totals per parent entered measure. De-identified Demographics and age areas utilization -Utilization across the number of pediatric sites, healthcare teams

Over a 3 month perriod
CHAMP app performance: Downtime
Tidsramme: Over a 3 month period

Product Performance Analytics measured through Any system downtime

Over a 3 month period
CHAMP app performance: Cybersecurity
Tidsramme: Over a 3 month period

Product Performance Analytics measured through Any reported breaches

Over a 3 month period
CHAMP app performance
Tidsramme: Quarterly review of CHAMP App Performance will be measure over the preceding 3 months for frequency of changes required

Product Performance Analytics measured through --Bug/defect rate or Version failure rates

Quarterly review of CHAMP App Performance will be measure over the preceding 3 months for frequency of changes required

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Lori Erickson, PhD, Director, Remote Health Solutions Children's Mercy

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. august 2023

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

24. august 2023

Først innsendt som oppfylte QC-kriteriene

11. september 2023

Først lagt ut (Faktiske)

13. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere